Please login to the form below
non-steroidal therapy
This page shows the latest non-steroidal therapy news and features for those working in and with pharma, biotech and healthcare.
Roche out-licenses lebrikizumab rights to Dermira
Other competition is also in the offing including GlaxoSmithKline's asthma therapy Nucala (mepolizumab) and non-steroidal anti-inflammatory tapinarof, which are both in mid-stage testing for atopic dermatitis, and
Latest news
-
FDA green light for Pfizer's eczema drug
Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.
-
Pfizer adds eczema drug with $5.2bn Anacor acquisition
Pfizer adds eczema drug with $5.2bn Anacor acquisition. Expands innovative products business with non-steroidal therapy Crisaborole. ... and if approved would be the first new non-steroidal therapy for the skin condition in more than 15 years.
-
Novartis wins childhood arthritis indication for Ilaris in EU
Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Account Director or Senior Account Director
-
Salary TBC
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Sudler London - Senior Medical Writer
-
Competitive
-
Account Manager
-
Negotiable
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Sudler London - Account Director
-
Competitive
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
Subscribe to our email news alerts
- Moving annual total (MAT)
- Key success factor (KSF)
- AZ prepares to file COPD triple, taking on rival GSK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Gilead targets hep B in half a billion dollar deal with Precision BioSciences
- Teva wins FDA OK for crucial migraine drug
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
